
|Articles|July 24, 2019
Versiti Acquires Cenetron Central Laboratories and Salus IRB
Advertisement
Versiti has announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB. The acquisition will not impact Cenetron’s 40 employees, and the laboratory will maintain its name and current location in Austin.
For more details, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
Is Artificial Intelligence Coming for Clinical Research?
3
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
4
The CRA Role’s Co-evolution With Clinical Trial Technology
5






.png)



.png)



.png)
.png)
